Sunshine Biopharma Inc. (SBFM)
2.47
-0.10 (-3.89%)
At close: Feb 20, 2025, 3:59 PM
2.47
0.00%
After-hours: Feb 20, 2025, 03:59 PM EST
undefined% (undefined)
| Bid | 2.4 |
| Market Cap | 6.69M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -127.9 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.54 |
| Volume | 39,295 |
| Avg. Volume (20D) | 696,208 |
| Open | 2.53 |
| Previous Close | 2.57 |
| Day's Range | 2.43 - 2.55 |
| 52-Week Range | 2.11 - 286.00 |
| Beta | undefined |
About SBFM
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast c...
Full Company ProfileAnalyst Forecast
According to 1 analyst ratings, the average rating for SBFM stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 507.29% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Sunshine Biopharma Inc. is scheduled to release its earnings on Mar 27, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+11.32%
Sunshine Biopharma shares are trading higher after...
Unlock content with
Pro Subscription
8 months ago
+37.89%
Sunshine Biopharma shares are trading higher after Texas Congressman Roger Williams disclosed a purchase in the company.
